IgG4 drives M2a macrophages to a regulatory M2b‐like phenotype: potential implication in immune tolerance

Background Macrophages can be converted in vitro into immunoregulatory M2b macrophages in the presence of immune complexes (ICs), but the role of the specific subclasses IgG1 or IgG4 in this phenotypic and functional change is not known. Objective We aimed to refine the original method by applying p...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Allergy (Copenhagen) 2019-03, Vol.74 (3), p.483-494
Hauptverfasser: Bianchini, Rodolfo, Roth‐Walter, Franziska, Ohradanova‐Repic, Anna, Flicker, Sabine, Hufnagl, Karin, Fischer, Michael Bernhard, Stockinger, Hannes, Jensen‐Jarolim, Erika
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:Background Macrophages can be converted in vitro into immunoregulatory M2b macrophages in the presence of immune complexes (ICs), but the role of the specific subclasses IgG1 or IgG4 in this phenotypic and functional change is not known. Objective We aimed to refine the original method by applying precisely defined ICs of the subclasses IgG4 or IgG1 constructed by two independent methods. Methods Monocyte‐derived macrophages (MDMs) were treated with M‐CSF, followed by IL‐4/IL‐13 to induce the M2a allergic phenotype. To mimic unspecific or allergen‐specific ICs, plates were coated with myeloma IgG1 or IgG4, or with grass pollen allergen Phl p 5 followed by recombinant human Phl p 5‐specific IgG1 or IgG4. M2a polarized macrophages were then added, cultured, and examined for cellular markers and cytokines by flow cytometry, ELISA, and rtPCR. Alternatively, immune complexes with IgG1 or IgG4 were formed using protein L. Results IgG4 ICs down regulated CD163 and CD206 on M2a cells, and significantly increased IL‐10, IL‐6, TNFα, and CCL1 secretion, indicating a shift to an M2b‐like phenotype. Treatment with IgG4 ICs resulted in expression of FcγRII and down modulation of FcγRII compared with IgG1 treated cells (P = 0.0335) or untreated cells (P 
ISSN:0105-4538
1398-9995
DOI:10.1111/all.13635